Buchumschlag

Pentostatin for the treatment of indolent lymphoproliferative disorders

Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Ea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ho, Anthony Dick (VerfasserIn) , Hensel, Manfred (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: [2006]
In: Seminars in hematology
Year: 2006, Jahrgang: 43, Pages: 2-10
ISSN:1532-8686
DOI:10.1053/j.seminhematol.2005.12.005
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1053/j.seminhematol.2005.12.005
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0037196305002623
Volltext
Verfasserangaben:Anthony D. Ho and Manfred Hensel

MARC

LEADER 00000caa a2200000 c 4500
001 1778266355
003 DE-627
005 20220820081511.0
007 cr uuu---uuuuu
008 211122s2006 xx |||||o 00| ||eng c
024 7 |a 10.1053/j.seminhematol.2005.12.005  |2 doi 
035 |a (DE-627)1778266355 
035 |a (DE-599)KXP1778266355 
035 |a (OCoLC)1341424070 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ho, Anthony Dick  |d 1948-  |e VerfasserIn  |0 (DE-588)108692477  |0 (DE-627)504904205  |0 (DE-576)19010466X  |4 aut 
245 1 0 |a Pentostatin for the treatment of indolent lymphoproliferative disorders  |c Anthony D. Ho and Manfred Hensel 
264 1 |c [2006] 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 22.11.2021 
520 |a Purine analogues have been shown to be active in a variety of B- and T-cell malignancies. Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism. ADA is present in all human tissues, with the highest levels in the lymphoid system. Early clinical trials with pentostatin used high doses for acute lymphoblastic leukemias, which were characterized by high levels of ADA. Through the efforts of a few investigators, low-dose regimens that are active and well tolerated for indolent lymphoid malignancies have been developed. Myelosuppressive adverse effects have been shown to be minimal using these schedules. Lymphoplasmacytic lymphoma (LL) is an indolent chronic B-cell lymphoproliferative disorder moderately responsive to alkylating agents. All of the purine analogues have shown activity in LL. However, the advantage of pentostatin over the other agents is the relatively specific toxicity to lymphoid cells and the paucity of myelosuppression as a single agent. No direct comparisons of the agents have been investigated, although pentostatin may be considered to be preferred since it has not been associated with toxicity to myeloid progenitors in colony assays. This is of significance for patients who might benefit from high-dose chemotherapy with autologous stem cell transplantation. 
700 1 |a Hensel, Manfred  |d 1964-  |e VerfasserIn  |0 (DE-588)1065849729  |0 (DE-627)816878307  |0 (DE-576)425541908  |4 aut 
773 0 8 |i Enthalten in  |t Seminars in hematology  |d Philadelphia, Pa. : Saunders, 2000  |g 43(2006), Seite S2-S10  |h Online-Ressource  |w (DE-627)346436486  |w (DE-600)2078098-9  |w (DE-576)099026112  |x 1532-8686  |7 nnas  |a Pentostatin for the treatment of indolent lymphoproliferative disorders 
773 1 8 |g volume:43  |g year:2006  |g pages:2-10  |g extent:9  |a Pentostatin for the treatment of indolent lymphoproliferative disorders 
856 4 0 |u https://doi.org/10.1053/j.seminhematol.2005.12.005  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S0037196305002623  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20211122 
993 |a Article 
994 |a 2006 
998 |g 1065849729  |a Hensel, Manfred  |m 1065849729:Hensel, Manfred  |d 910000  |d 910100  |e 910000PH1065849729  |e 910100PH1065849729  |k 0/910000/  |k 1/910000/910100/  |p 2  |y j 
998 |g 108692477  |a Ho, Anthony Dick  |m 108692477:Ho, Anthony Dick  |d 910000  |d 910100  |e 910000PH108692477  |e 910100PH108692477  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1778266355  |e 4004771390 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"roleDisplay":"VerfasserIn","display":"Ho, Anthony Dick","role":"aut","family":"Ho","given":"Anthony Dick"},{"display":"Hensel, Manfred","roleDisplay":"VerfasserIn","role":"aut","family":"Hensel","given":"Manfred"}],"title":[{"title":"Pentostatin for the treatment of indolent lymphoproliferative disorders","title_sort":"Pentostatin for the treatment of indolent lymphoproliferative disorders"}],"note":["Gesehen am 22.11.2021"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1778266355","language":["eng"],"name":{"displayForm":["Anthony D. Ho and Manfred Hensel"]},"origin":[{"dateIssuedDisp":"[2006]","dateIssuedKey":"2006"}],"id":{"eki":["1778266355"],"doi":["10.1053/j.seminhematol.2005.12.005"]},"physDesc":[{"extent":"9 S."}],"relHost":[{"pubHistory":["Nachgewiesen 37.2000 -"],"part":{"pages":"2-10","year":"2006","extent":"9","volume":"43","text":"43(2006), Seite S2-S10"},"disp":"Pentostatin for the treatment of indolent lymphoproliferative disordersSeminars in hematology","type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 10.02.25"],"recId":"346436486","language":["eng"],"title":[{"title_sort":"Seminars in hematology","title":"Seminars in hematology"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Philadelphia, Pa.","dateIssuedDisp":"2000-","publisher":"Saunders","dateIssuedKey":"2000"}],"id":{"eki":["346436486"],"zdb":["2078098-9"],"issn":["1532-8686"]}}]} 
SRT |a HOANTHONYDPENTOSTATI2006 

Ähnliche Einträge